(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.5%.
Pelthos Therapeutics's earnings in 2026 is -$23,581,284.On average, 7 Wall Street analysts forecast PTHS's earnings for 2026 to be -$16,913,644, with the lowest PTHS earnings forecast at -$34,745,181, and the highest PTHS earnings forecast at -$1,768,121. On average, 5 Wall Street analysts forecast PTHS's earnings for 2027 to be $7,203,523, with the lowest PTHS earnings forecast at $3,060,456, and the highest PTHS earnings forecast at $9,644,295.
In 2028, PTHS is forecast to generate $13,772,053 in earnings, with the lowest earnings forecast at $13,231,973 and the highest earnings forecast at $14,177,114.